PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Net income growth exceeding 1.5x Biotechnology median of 3.09%. Joel Greenblatt would see it as a clear outperformance relative to peers.
8.54%
D&A growth of 8.54% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
100.00%
Deferred tax growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would see a difference that might matter for future cash flow if significant.
48.65%
SBC growth of 48.65% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
-142.09%
Working capital is shrinking yoy while Biotechnology median is -75.99%. Seth Klarman would see an advantage if sales remain robust.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
-84.29%
Other WC usage shrinks yoy while Biotechnology median is -69.27%. Seth Klarman would see an advantage if top-line is stable or growing.
47.93%
Under 50% of Biotechnology median of 9.38% if negative or well above if positive. Jim Chanos would flag potential major accounting illusions or revaluations overshadowing underlying performance.
1.55%
Positive CFO growth while Biotechnology median is negative at -15.82%. Peter Lynch would see a notable cash advantage in a challenging sector environment.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Debt repayment yoy declines while Biotechnology median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
1131.77%
Issuance growth of 1131.77% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or acquisitions financed by new shares.
No Data
No Data available this quarter, please select a different quarter.